Key result
Pathogenic non-truncating variants in MYBPC3 showed alterations in RNA splicing or protein stability in 45% of cases, which can be linked to pathogenicity with 100% and 94% specificity, respectively.
Why the study?
Defining whether specific MYBPC3 gene variants found in patients are pathogenic remains challenging, limiting the reach of cardiovascular genetics in managing hypertrophic cardiomyopathy.
Alteration of RNA splicing or protein stability caused by MYBPC3 variants provides strong evidence of their pathogenicity, which can help reclassify variants of uncertain significance in hypertrophic cardiomyopathy.
May aid MYBPC3 VUS reclassification in HCM; animal data leaves clinical translation open.
Hypertrophic cardiomyopathy (HCM) is the most common inherited cardiac disease. Mutations in MYBPC3 , the gene encoding cardiac myosin-binding protein C (cMyBP-C), are a leading cause of HCM. However, it remains challenging to define whether specific gene variants found in patients are pathogenic or not, limiting the reach of cardiovascular genetics in the management of HCM. Here, we have examined cMyBP-C haploinsufficiency drivers in 68 clinically annotated non-truncating variants of MYBPC3 . We find that 45% of the pathogenic variants show alterations in RNA splicing or protein stability, which can be linked to pathogenicity with 100% and 94% specificity, respectively. Relevant for variant annotation, we uncover that 9% of non-truncating variants of MYBPC3 currently classified as of uncertain significance induce one of these molecular phenotypes. We propose that alteration of RNA splicing or protein stability caused by MYBPC3 variants provide strong evidence of their pathogenicity, leading to improved clinical management of HCM patients and their families.
No takes yet. Share an insight, caveat, or question.
Suay‐Corredera et al. (2020) studied Hypertrophic cardiomyopathy (n=141). Pathogenic MYBPC3 variants vs. Non-pathogenic MYBPC3 variants was evaluated on Alterations in RNA splicing or protein stability. Pathogenic non-truncating variants in MYBPC3 showed alterations in RNA splicing or protein stability in 45% of cases, which can be linked to pathogenicity with 100% and 94% specificity, respectively.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: